FDA now says impurity level in Zantac and other antacids is too high

2nd October 2019 Uncategorised 0

The FDA has changed its tune about the levels of a suspected carcinogen in Zantac and generic ranitidine drugs. Instead of just a little NDMA with a very low risk, the agency says its new “early, limited testing” has found unacceptable levels of NDMA in ranitidine samples.

More: FDA now says impurity level in Zantac and other antacids is too high
Source: fierce